Yiling Pharma: Lianhua Qingwen's Access to Ukrainian Market Marks Its Accelerated Global Expansion
Yiling Pharmaceutical discloses on Friday that it has received the Approval of Registration approved and issued by the certification authority in Ukraine - ТЕСТМЕТРСТАНДАРТ, which indicates that the Company's patented product of "Lianhua Qingwen Capsules" meets the Ukrainian registration standards for dietary supplements.
As the leading product of Yiling Pharmaceutical, Lianhua Qingwen is dedicated to the treatment of relevant diseases including cold, flu and COVID-19. Since the outbreak of COVID-19, Lianhua Qingwen Capsules (Granules) has been recommended by the Diagnosis and Treatment Protocol for COVID-19 (Trial Version 4/5/6/7/8) jointly issued by the National Health Commission and National Administration of Traditional Chinese Medicine, and the diagnosis and treatment protocols for COVID-19 in more than 20 provinces and cities, making it the most frequently recommended Chinese patent medicine. In April 2020, Lianhua Qingwen Capsules/Granules were approved to add "mild and moderate coronavirus disease 2019 (COVID-19)" to its originally approved indications by the National Medical Products Administration of China.
The "Efficacy and safety of Lianhua Qingwen Capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial" has been carried out by the three distinguished academicians of Zhong Nanshan, Li Lanjuan, and Zhang Boli partnering with 23 hospitals admitting COVID-19 patients, and the results were published on the European renowned magazine Phytomedicine in May this year, showing that Lianhua Qingwen can greatly relieve the clinical symptoms of COVID-19 such as fever, fatigue, cough, etc., obviously improve the pulmonary imaging lesions, shorten
Currently, Lianhua Qingwen Capsules has entered the markets in nearly 20 countries and regions such as Canada, Russia, the Philippines, Kuwait, Kyrgyzstan, etc. In Kuwait, Lianhua Qingwen has been approved to add COVID-19 to its originally approved indications; while in Uzbekistan, Lianhua Qingwen has been selected into the Ministry of Health's drugs against COVID-19, and approved to be imported without registration and treat COVID-19 patients.
According to Yiling Pharmaceutical, the Ukraine's approval of Lianhua Qingwen Capsules for registration as a dietary supplement reflects the Company's eligibility to market the product in Ukraine, bringing positive impacts on the Company's global market expansion.